Sökning: WFRF:(Lopez Sendon Jose) > Efficacy of apixaba...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03629naa a2200457 4500 | |
001 | oai:DiVA.org:uu-188429 | |
003 | SwePub | |
008 | 121217s2012 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1884292 URI |
024 | 7 | a https://doi.org/10.1093/eurheartj/ehs2742 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Hohnloser, Stefan H.4 aut |
245 | 1 0 | a Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation :b insights from the ARISTOTLE trial |
264 | c 2012-08-29 | |
264 | 1 | b Oxford University Press (OUP),c 2012 |
338 | a print2 rdacarrier | |
520 | a AimsAtrial fibrillation (AF) is common among patients with impaired renal function. Apixaban, a novel oral anticoagulant with partial renal excretion, was compared with warfarin and reduced the rate stroke, death and bleeding in the ARISTOTLE trial. We evaluated these outcomes in relation to renal function.Methods and resultsBaseline glomerular filtration rate (GFR) was estimated using the Cockcroft–Gault and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations as well as cystatin C measurements. According to baseline Cockcroft–Gault, there were 7518 patients (42%) with an estimated GFR (eGFR) of >80 mL/min, 7587 (42%) between >50 and 80 mL/min, and 3017 (15%) with an eGFR of ≤50 mL/min. The rate of cardiovascular events and bleeding was higher at impaired renal function (≤80 mL/min). Apixaban was more effective than warfarin in preventing stroke or systemic embolism and reducing mortality irrespective of renal function. These results were consistent, regardless of methods for GFR estimation. Apixaban was associated with less major bleeding events across all ranges of eGFRs. The relative risk reduction in major bleeding was greater in patients with an eGFR of ≤50 mL/min using Cockcroft–Gault {hazard ratio (HR) 0.50 [95% confidence interval (CI) 0.38–0.66], interaction P = 0.005} or CKD-EPI equations [HR 0.48 (95% CI 0.37–0.64), interaction P = 0.003].ConclusionIn patients with AF, renal impairment was associated with increased risk of cardiovascular events and bleeding. When compared with warfarin, apixaban treatment reduced the rate of stroke, death, and major bleeding, regardless of renal function. Patients with impaired renal function seemed to have the greatest reduction in major bleeding with apixaban. | |
653 | a Atrial fibrillation | |
653 | a Anticoagulation | |
653 | a Stroke prevention | |
653 | a Bleeding | |
653 | a Apixaban | |
700 | 1 | a Hijazi, Ziadu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)ziahi940 |
700 | 1 | a Thomas, Laine4 aut |
700 | 1 | a Alexander, John H.4 aut |
700 | 1 | a Amerena, John4 aut |
700 | 1 | a Hanna, Michael4 aut |
700 | 1 | a Keltai, Matyas4 aut |
700 | 1 | a Lanas, Fernando4 aut |
700 | 1 | a Lopes, Renato D.4 aut |
700 | 1 | a Lopez-Sendon, Jose4 aut |
700 | 1 | a Granger, Christopher B.4 aut |
700 | 1 | a Wallentin, Larsu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)larswall |
710 | 2 | a Uppsala universitetb Uppsala kliniska forskningscentrum (UCR)4 org |
773 | 0 | t European Heart Journald : Oxford University Press (OUP)g 33:22, s. 2821-2830q 33:22<2821-2830x 0195-668Xx 1522-9645 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-188429 |
856 | 4 8 | u https://doi.org/10.1093/eurheartj/ehs274 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.